The New England journal of medicine
-
Randomized Controlled Trial Multicenter Study Comparative Study
Closure or medical therapy for cryptogenic stroke with patent foramen ovale.
The prevalence of patent foramen ovale among patients with cryptogenic stroke is higher than that in the general population. Closure with a percutaneous device is often recommended in such patients, but it is not known whether this intervention reduces the risk of recurrent stroke. ⋯ In patients with cryptogenic stroke or TIA who had a patent foramen ovale, closure with a device did not offer a greater benefit than medical therapy alone for the prevention of recurrent stroke or TIA. (Funded by NMT Medical; ClinicalTrials.gov number, NCT00201461.).
-
Randomized Controlled Trial Multicenter Study
Placebo-controlled trial of oral laquinimod for multiple sclerosis.
Two proof-of-concept clinical trials have provided evidence that laquinimod reduces disease activity in patients with relapsing-remitting multiple sclerosis. ⋯ In this phase 3 study, oral laquinimod administered once daily slowed the progression of disability and reduced the rate of relapse in patients with relapsing-remitting multiple sclerosis. (Funded by Teva Pharmaceutical Industries; ClinicalTrials.gov number, NCT00509145.).
-
Editorial Comment
Patent foramen ovale closure--closing the door except for trials.